Clinical Trial Update: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating Vibecotamab (XmAb14045) for patients with measurable residual disease-positive acute myeloid leukemia and myelodysplasti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Vibecotamab (XmAb14045) (XmAb14045)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: AML, MDS | Phase 2 | Status: ACTIVE_NOT_RECRUITING